BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36470801)

  • 1. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
    Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
    Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
    Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
    Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
    J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Damin AP; Zancan M; Melo MP; Biazus JV
    Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy.
    Dux J; Habibi M; Malik H; Jacobs L; Wright PA; Lange J; Camp M; O'Donnell M; Sun B; Tran HT; Euhus D
    Breast Cancer Res Treat; 2023 Nov; 202(2):267-273. PubMed ID: 37531016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
    Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
    Chun JW; Kim J; Chung IIY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Breast Cancer Res Treat; 2021 Jun; 187(3):647-655. PubMed ID: 33966181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
    Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
    Breast J; 2022; 2022():1507881. PubMed ID: 36051467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy.
    Almahariq MF; Levitin R; Quinn TJ; Chen PY; Dekhne N; Kiran S; Desai A; Benitez P; Jawad MS; Gustafson GS; Dilworth JT
    Ann Surg Oncol; 2021 Feb; 28(2):930-940. PubMed ID: 32712895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
    Lu X; He M; Yu L; Gou Z
    Cancer; 2023 May; 129(10):1492-1501. PubMed ID: 36807239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.
    Cabıoğlu N; Karanlık H; Yıldırım N; Müslümanoğlu M; Çakmak Karadeniz G; Trabulus Can D; Tükenmez M; Ersoy YE; Uras C; Zengel B; Emiroğlu S; Polat AK; Yeniay L; Özkurt E; Kara H; İbiş K; Aydıner A; Özmen V; İğci A
    Eur J Surg Oncol; 2021 Oct; 47(10):2506-2514. PubMed ID: 34217580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.